{
  "id": 9215276,
  "title": "Cytokinetics EVP Fady Malik sells $239k in company stock",
  "url": "https://urgent.news/2026/09/22/cytokinetics-evp-fady-malik-sells-239k-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-22T22:45:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/cytokinetics-evp-fady-malik-sells-239k-in-company-stock-93CH-4911806"
  },
  "original_language": "en",
  "account": "Cytokinetics' Executive Vice President of Research & Development, Fady Ibraham Malik, sold 3,500 shares of the company's common stock on September 22, 2026, for a total value of $239,015. The stock sale came as part of a filing where Malik acquired 3,500 shares through non-qualified stock options at an exercise price of $7.80 per share, resulting in a total value of $27,300. Following these transactions, Malik currently holds 153,902 shares of Cytokinetics common stock. In addition, Malik benefits from owning 23,386 non-qualified stock options. Cytokinetics reported strong second-quarter sales of Myqorzo, amounting to $25.3 million, which exceeded Bloomberg consensus estimates by 65.2% during its initial full quarter on the market. This positive result led Barclays to raise its price target on Cytokinetics shares to $110, while maintaining an Overweight rating.",
  "summary": null,
  "key_points": [
    "Cytokinetics EVP Fady Malik sold 3,500 shares for $239,015",
    "Malik acquired shares via non-qualified stock options",
    "Cytokinetics Q2 sales exceeded estimates by 65.2%"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}